Skip to main content
editorial
. 2017 Dec 18;9(4):4280–4281. doi: 10.18632/oncotarget.23403

Figure 1. Therapies targeting PR1.

Figure 1

PR1 is derived from neutrophil elastase (NE) and proteinase 3 (P3), and is presented on human leukocyte antigen (HLA)-A*0201. Although PR1 peptide vaccine is the only PR1-targeting therapy that has been tested in clinical trials, a number of therapies have been developed to target PR1 and have shown promise in pre-clinical in vivo models, including a T cell receptor (TCR)-like monoclonal antibody and a chimeric antigen receptor (CAR) T cell that target PR1/HLA-A2.